PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
125.83%
Net income growth above 1.5x VET's 74.93%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
16.33%
D&A growth well above VET's 18.78%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
200.00%
Well above VET's 54.52% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-67.95%
Negative yoy SBC while VET is 19.11%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
395.28%
Well above VET's 229.04% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
94.37%
AR growth of 94.37% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
791.67%
Growth well above VET's 229.04%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-52.50%
Both negative yoy, with VET at -15.43%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
86.32%
Operating cash flow growth at 75-90% of VET's 106.95%. Bill Ackman would recommend further refinements to match competitor’s CFO gains.
12.10%
Some CapEx rise while VET is negative at -146.78%. John Neff would see competitor possibly building capacity while we hold back expansions.
-80.43%
Both yoy lines negative, with VET at -236.30%. Martin Whitman sees an overall caution or integration phase for both companies’ expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-107.62%
We reduce yoy other investing while VET is 141.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-17.57%
Both yoy lines negative, with VET at -110.59%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.82%
Buyback growth of 43.82% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.